TSThomas S. G. Sehested

Thomas S. G. Sehested

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Thomas S. G. Sehested has a total of 65 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Frailty, Treatments, and Outcomes in Older Patients With Myocardial Infarction: A Nationwide Registry‐Based Study

    by Daniel Mølager Christensen, Jarl Emanuel Strange, Alexander Christian Falkentoft, Mohamad El‐Chouli, Pauline B. Ravn, Anne Christine Ruwald, Emil Fosbøl, Lars Køber, Gunnar Gislason, Thomas S. G. Sehested, et al.

    Background: Guidelines recommend that patients with myocardial infarction (MI) receive equal care regardless of age. However, withholding treatment may be justified in elderly and frail patients. This study aimed to investigate trends in treatments and outcomes of older patients with MI according to frailty. Methods and Results: All patients aged ≥75 years with first‐time MI during 2002 to 2021 were identified through Danish nationwide registries. Frailty was categorized using the Hospital Frailty Risk Score. One‐year risk and hazard ratios (HRs) for days 0 to 28 and 29 to 365 were calculated for all‐cause death. A total of 51 022 patients with MI were included (median, 82 years; 50.2% women). Intermediate/high frailty increased from 26.7% in 2002 to 2006 to 37.1% in 2017 to 2021. Use of treatment increased substantially regardless of frailty: for example, 28.1% to 48.0% (statins), 21.8% to 33.7% (dual antiplatelet therapy), and 7.6% to 28.0% (percutaneous coronary intervention) for high frailty (all P ‐trend P ‐trend P ‐interaction=0.23). When additionally adjusted for treatment, HRs attenuated to 0.74 (0.67–0.83), 0.83 (0.74–0.94), and 0.78 (0.58–1.05), respectively, indicating that increased use of treatment may account partially for the observed improvements. Conclusions: Use of guideline‐based treatments and outcomes improved concomitantly in older patients with MI, irrespective of frailty. These results indicate that guideline‐based management of MI may be reasonable in the elderly and frail.


  • Open Access

    Lifetime risk of comorbidity in patients with simple congenital heart disease: a Danish nationwide study

    by Mohamad El-Chouli, Alessandra Meddis, Daniel M Christensen, Thomas A Gerds, Thomas Sehested, Morten Malmborg, Matthew Phelps, Casper N Bang, Ole Ahlehoff, Christian Torp-Pedersen, et al.

    Aims: In a continuously ageing population of patients with congenital heart disease (CHD), understanding the long-term risk of morbidity is crucial. The aim of this study was to compare the lifetime risks of developing comorbidities in patients with simple CHD and matched controls.Methods and results: Using the Danish nationwide registers spanning from 1977 to 2018, simple CHD cases were defined as isolated atrial septal defect (ASD), ventricular septal defect (VSD), pulmonary stenosis, or patent ductus arteriosus in patients surviving until at least 5 years of age. There were 10 controls identified per case. Reported were absolute lifetime risks and lifetime risk differences (between patients with simple CHD and controls) of incident comorbidities stratified by groups and specific cardiovascular comorbidities. Of the included 17 157 individuals with simple CHD, the largest subgroups were ASD (37.7%) and VSD (33.9%), and 52% were females. The median follow-up time for patients with CHD was 21.2 years (interquartile range: 9.4–39.0) and for controls, 19.8 years (9.0–37.0). The lifetime risks for the investigated comorbidities were higher and appeared overall at younger ages for simple CHD compared with controls, except for neoplasms and chronic kidney disease. The lifetime risk difference among the comorbidity groups was highest for neurological disease (male: 15.2%, female: 11.3%), pulmonary disease (male: 9.1%, female: 11.7%), and among the specific comorbidities for stroke (male: 18.9%, female: 11.4%). The overall risk of stroke in patients with simple CHD was mainly driven by ASD (male: 28.9%, female: 17.5%), while the risks of myocardial infarction and heart failure were driven by VSD. The associated lifetime risks of stroke, myocardial infarction, and heart failure in both sexes were smaller in invasively treated patients compared with untreated patients with simple CHD.Conclusion: Patients with simple CHD had increased lifetime risks of all comorbidities compared with matched controls, except for neoplasms and chronic kidney disease. These findings highlight the need for increased attention towards early management of comorbidity risk factors.


  • Open Access

    Long-term mortality, cardiovascular events, and bleeding in stable patients 1 year after myocardial infarction: a Danish nationwide study

    by Daniel Mølager Christensen, Anne-Marie Schjerning, Lærke Smedegaard, Mette Gitz Charlot, Pauline B Ravn, Anne Christine Ruwald, Emil Fosbøl, Lars Køber, Christian Torp-Pedersen, Morten Schou, et al.

    Outcomes after myocardial infarction (MI) improved during recent decades alongside better risk factor management and implementation of guideline-recommended treatments. However, it is unknown whether this applies to stable patients who are event-free 1 year after MI. Using nationwide Danish registries, we included all patients with first-time MI during 2000–17 who survived 1 year free from bleeding and cardiovascular events (n = 82 108, median age 64 years, 68.2% male). Follow-up started 1 year after MI and continued through January 2022. Crude risks of mortality, cardiovascular events, and bleeding were estimated in consecutive 3-year periods. Standardized risks were calculated with respect to the distribution of age, sex, comorbidities, and treatments in the latter period. Guideline-recommended treatment use increased during the study period: e.g. statins (68.6–92.5%) and percutaneous coronary intervention (23.9–68.2%). The crude 5-year risks of outcomes decreased (all P-trend <0.001): Mortality, 18.6% (95% confidence interval [CI]: 17.9–19.2) to 12.5% (CI: 11.9–13.1); Recurrent MI, 7.5% (CI: 7.1–8.0) to 5.5% (CI: 5.1–6.0); Bleeding, 3.9% (CI: 3.6–4.3) to 2.7% (CI: 2.4–3.0). Crude 5-year risk of mortality in 2015–17 was as low as 2.6% for patients aged <60 years. Use of guideline-recommended treatments was associated with improved outcomes: After standardization for changes in treatments, 5-year risk of mortality in 2000–02 was 15.5% (CI: 14.9–16.2). For patients who were event-free 1 year after MI, the long-term risks of mortality, cardiovascular events, and bleeding decreased significantly, along with an improved use of guideline-recommended treatments between 2000 and 2017. In the most recent period, 1 year after MI, the risk of additional events was lower than previously reported. Overview of the study design and the main findings. MI, myocardial infarction.


  • Open Access

    Trends in Use of Cardioprotective Medication in Peripheral Artery Disease: A Nationwide Study

    by Sadaf Kamil, Thomas S. G. Sehested, Kim Houlind, Jens F. Lassen, Gunnar H. Gislason, Helena Dominguez

    Background: Guideline‐based cardioprotective medical therapy is intended to reduce the burden of adverse cardiovascular and limb outcomes in patients with peripheral artery disease (PAD). However, contemporary data describing trends in use of medication remains limited. The present study, therefore, aims to investigate changes in use of cardioprotective medication in PAD. Methods and Results: By using Danish national healthcare registries, we identified all patients with first‐time diagnosis of PAD (1997–2016) and classified them into two groups: (1) PAD+ that includes all patients with PAD with a history of cardiovascular disease, ie, myocardial infarction, atrial fibrillation, and stroke (n=162 627); and (2) PAD (n=87 935) that comprise patients without a history of cardiovascular disease. We determined the use of medication in the first 12 months after the incident diagnosis of PAD and estimated age standardized 1‐year mortality rates. Our results showed increase in use of cardioprotective medication throughout the study period in both groups. However, PAD+ had a higher use of medication (acetylsalicylic acid, 3.5%–48.4%; Clopidogrel, 0%–17.6%; vitamin K antagonists, 0.9%–7.8%; new oral anticoagulants, 0.0%–10.1%; Statins, 1.9%–58.1%; angiotensin‐converting enzyme inhibitors, 1.2%–20.6%), compared with PAD (acetylsalicylic acid, 2.9%–54.4%; Clopidogrel, 0%–11.9%; vitamin K antagonists, 0.9%–2.4%; new oral anticoagulants, 0.0%–3.4%; Statins, 1.5%–56.9%; angiotensin‐converting enzyme, 0.9%–17.2%), respectively. Furthermore, 1‐year mortality rates in PAD declined with increased use of medications during study. Conclusions: In this nationwide study, use of cardioprotective medication increased considerably with time, but compared to patients with other atherosclerotic diseases, there remains an underuse of guideline‐based medical therapy in patients with PAD.


  • Open Access

    Diabetes and risk of peripheral artery disease in patients undergoing first-time coronary angiography between 2000 and 2012 – a nationwide study

    by Sadaf Kamil, Thomas S. G. Sehested, Nicholas Carlson, Kim Houlind, Jens F. Lassen, Casper N. Bang, Helena Dominguez, Christian T. Pedersen, Gunnar H. Gislason

    Background: The risk of peripheral artery disease (PAD) in patients with diabetes mellitus (DM) and coronary artery disease (CAD) is an important and inadequately addressed issue. Our aim is to examine the impact of DM on risk of PAD in patients with different degrees of CAD characterized by coronary angiography (CAG). Methods: Using nationwide registers we identified all patients aged ≥18 years, undergoing first time CAG between 2000 and 2012. Patients were categorized into DM/Non-DM group, and further classified into categories according to the degree of CAD i.e., no-vessel disease, single-vessel disease, double-vessel disease, triple-vessel disease, and diffuse disease. Risk of PAD was estimated by 5-year cumulative-incidence and adjusted multivariable Cox-regression models. Results: We identified 116,491 patients undergoing first-time CAG. Among these, a total of 23.969 (20.58%) had DM. Cumulative-incidence of PAD among DM patients vs. non-DM were 8.8% vs. 4.9% for no-vessel disease, 8.2% vs. 4.8% for single-vessel disease, 10.2% vs. 6.0% for double-vessel disease, 13.0% vs. 8.4% for triple-vessel disease, and 6.8% vs. 6.1% for diffuse disease, respectively. For all patients with DM, the cox-regression analysis yielded significantly higher hazards of PAD compared with non-DM patients with HR 1.70 (no-vessel disease), 1.96 (single-vessel disease), 2.35 (double-vessel disease), 2.87 (triple-vessel disease), and 1.46 (diffuse disease), respectively (interaction-p 0.042). Conclusion: DM appears to be associated with increased risk of PAD in patients with and without established CAD, with increasing risk in more extensive CAD. This observation indicates awareness on PAD risk in patients with DM, especially among patients with advanced CAD.


  • 5259Continuing decline in incidence of recurrent myocardial infarction, stroke, and death following first myocardial infarction: a 15-year nationwide cohort study

    by T S G Sehested, A N Bonde, L Smedegaard, E L Fosboel, M G Charlot, C Torp-Pedersen, H A Hlatky, G H Gislason

    Background: Improvements in treatment after myocardial infarction (MI) have had a beneficial effect on the prognosis, but it is unclear whether the prognosis is continuing to improve.

  • P2562Cost-effectiveness of canakinumab to prevent recurrent cardiovascular events

    by T S G Sehested, J Bjerre, A Chang, S Ku, A Jahansouz, D K Owens, M A Hlatky, J D Goldhaber-Fiebert

    Background: The anti-inflammatory monoclonal antibody canakinumab was found in the CANTOS trial to significantly reduce the risk of recurrent cardiovascular events among patients with previous myocardial infarction (MI) who had a high-sensitivity C-reactive protein (hsCRP) >2mg/L.

  • Long‐term use of proton pump inhibitors, dose–response relationship and associated risk of ischemic stroke and myocardial infarction

    by T. S. G. Sehested, T. A. Gerds, E. L. Fosbøl, P. W. Hansen, M. G. Charlot, N. Carlson, M. A. Hlatky, C. Torp‐Pedersen, G. H. Gislason

    Background: Use of proton pump inhibitors (PPIs) has been associated with cardiovascular disease amongst patients not on antiplatelet therapy. The associations of PPI use, duration and dose, with risk of first‐time ischemic stroke and myocardial infarction (MI) are poorly understood.Methods: All Danish individuals with no prior history of MI or stroke, who had an elective upper gastrointestinal endoscopy performed between 1997 and 2012, were identified from nationwide registries. We used multiple Poisson regression to test associations with current PPI use and its dose and used multiple cause‐specific Cox regression and g‐formula methods to analyze long‐term use.Results: Amongst 214 998 individuals, during a median follow‐up of 5.8 years, there were 7916 ischemic strokes and 5608 MIs. Current PPI exposure was associated with significantly higher rates of both ischemic stroke (Hazard ratio (HR) 1.13; 95% confidence interval (CI) 1.08–1.19) and MI (HR 1.31, CI 1.23–1.39) after adjusting for age, sex, comorbidities and concomitant medication. High‐dose PPI was associated with increased rates of ischemic stroke (HR 1.31, CI 1.21–1.42) and MI (HR 1.43, CI 1.30–1.57). Histamine H2 receptor antagonists (H2RAs) use was not significantly associated with ischemic stroke (HR 1.02, CI 0.84–1.24) or MI (HR 1.15, CI 0.92–1.43). Long‐term users of PPIs, compared with nonusers, had a 29% (CI 5%‐59%) greater absolute risk of ischemic stroke and a 36% (CI 7%‐73%) greater risk of MI within a 6‐month period.Conclusion: Use of PPIs was associated with increased risks of first‐time ischemic stroke and MI, particularly amongst long‐term users and at high doses.


  • Open Access

    Reply: proton‐pump inhibitor use and the risk of first‐time ischemic stroke in the general population

    by T. S. G. Sehested, M. A. Hlatky, N. Carlson, G. H. Gislason

    Click here to view the Letter to the Editor by Dr. Dai et al.


  • Identifying Drug–Drug Interactions by Data Mining

    by Peter Wæde Hansen, Line Clemmensen, Thomas S.G. Sehested, Emil Loldrup Fosbøl, Christian Torp-Pedersen, Lars Køber, Gunnar H. Gislason, Charlotte Andersson

    Background—: Knowledge about drug–drug interactions commonly arises from preclinical trials, from adverse drug reports, or based on knowledge of mechanisms of action. Our aim was to investigate whether drug–drug interactions were discoverable without prior hypotheses using data mining. We focused on warfarin–drug interactions as the prototype. Methods and Results—: We analyzed altered prothrombin time (measured as international normalized ratio [INR]) after initiation of a novel prescription in previously INR-stable warfarin-treated patients with nonvalvular atrial fibrillation. Data sets were retrieved from clinical work. Random forest (a machine-learning method) was set up to predict altered INR levels after novel prescriptions. The most important drug groups from the analysis were further investigated using logistic regression in a new data set. Two hundred and twenty drug groups were analyzed in 61 190 novel prescriptions. We rediscovered 2 drug groups having known interactions (β-lactamase-resistant penicillins [dicloxacillin] and carboxamide derivatives) and 3 antithrombotic/anticoagulant agents (platelet aggregation inhibitors excluding heparin, direct thrombin inhibitors [dabigatran etexilate], and heparins) causing decreasing INR. Six drug groups with known interactions were rediscovered causing increasing INR (antiarrhythmics class III [amiodarone], other opioids [tramadol], glucocorticoids, triazole derivatives, and combinations of penicillins, including β-lactamase inhibitors) and two had a known interaction in a closely related drug group (oripavine derivatives [buprenorphine] and natural opium alkaloids). Antipropulsives had an unknown signal of increasing INR. Conclusions—: We were able to identify known warfarin–drug interactions without a prior hypothesis using clinical registries. Additionally, we discovered a few potentially novel interactions. This opens up for the use of data mining to discover unknown drug–drug interactions in cardiovascular medicine.